Skip to main content
Caplight Logo









Biodol Therapeutics

Biodol Therapeutics

Private
MontarnaudHealthcare & Life Scienceshttps://biodol.eu/

Last Round

VC Round

May 21, 2024

Total Funding Raised

$5.36M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Biodol Therapeutics is a biotechnology company that develops first-in-class compounds for the treatment of chronic pain by targeting the FLT3 receptor.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryneuropathic painchronic painnon-opioidFLT3 inhibitornegative allosteric modulatorNAMsmall-molecule drugpain managementbiopharmaclinical-stage biotechpainkiller alternativesopioid-sparingin silico screening

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Biodol Therapeutics Comparables

Compare Biodol Therapeutics with similar companies based on industry and business-model similarity.

Biodol Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Latigo Biotherapeutics
81%
Halene Therapeutics
77%
Concentric Analgesics
64%

Biodol Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMay 21, 2024
Series AAug 31, 2020

Biodol Therapeutics Investors

Notable investors and investment history

Biodol Therapeutics investors
InvestorRounds
V-Bio VenturesVC Round, Series A
BpifranceVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 23, 2026

    Monthly visitors grew 44% MoM, from 953 to 1.4K.

  • May 18, 2026

    Monthly visitors increased 548% MoM.

Biodol Therapeutics Filings

Explore SEC and related filing metadata, where available.

Biodol Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Biodol Therapeutics's valuation, stock price, and market status.

Is Biodol Therapeutics a public or private company?

Biodol Therapeutics is a private company.

What is the current stock price of Biodol Therapeutics?

Biodol Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Biodol Therapeutics worth (valuation)?

Valuation information for Biodol Therapeutics is not publicly available.

Can I buy Biodol Therapeutics stock?

Biodol Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Biodol Therapeutics's last funding round?

Biodol Therapeutics's most recent funding round was VC Round on May 21, 2024.

Who are the main investors in Biodol Therapeutics?

Key investors in Biodol Therapeutics include V-Bio Ventures.

Will Biodol Therapeutics IPO soon?

No public IPO plans have been announced for Biodol Therapeutics.

How can I track Biodol Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Biodol Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMontarnaud
Employee Range7
Year Founded2015
Last FundingMay 21, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?